As the world continues to grapple with the fallout from the global pandemic, the healthcare sector is becoming an increasingly appealing prospect for investors. One company that warrants a closer look is Charles River Laboratories International (CRL), a US-based firm operating in the healthcare sector’s diagnostics and research industry. With a market cap of $8.55 billion, CRL is a key player in its field.
Currently trading at $167.28, CRL’s stock has experienced a subtle shift of 1.93 (0.01%) in its price. The company’s 52-week range is between $151.99 and $270.95, providing a broad spectrum for potential investors to consider. The forward P/E stands at 16.29. However, other essential valuation metrics such as trailing P/E, PEG ratio, price/book, price/sales, and EV/EBITDA are unavailable, making a comprehensive valuation analysis a bit challenging.
In terms of performance, CRL’s revenue growth has declined slightly by 1.10%. The company’s EPS stands at 0.20, and the return on equity is at 0.71%. One of the highlights of CRL’s performance is its robust free cash flow, which stands at a substantial $517,329,984.00. Despite these figures, the company does not offer a dividend yield, having a payout ratio of 0%.
On the analyst front, CRL has received three buy ratings, with sixteen hold ratings and one sell rating. The target price range for the stock is set between $130.00 – $260.12 with an average target of $183.23, indicating a potential upside/downside of 9.53%.
Looking at technical indicators, CRL’s 50-day moving average is $167.22, and its 200-day moving average is $192.69. The RSI (14) is 22.35, while the MACD and signal line are at 1.07 and 1.08, respectively.
Charles River Laboratories International operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). They provide a range of services from drug discovery, non-clinical development, safety testing services, to specialized testing of biologics. The company’s operations are wide-reaching, spanning the United States, Europe, Canada, the Asia Pacific, and internationally.
Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories International is deeply entrenched in the healthcare diagnostics and research industry. The company presents a compelling opportunity for investors looking for a foothold in the healthcare sector. However, potential investors should also consider the company’s slightly declining revenue growth and lack of dividend yield. With a broad spectrum of analyst ratings and a considerable potential upside, CRL is a stock worth keeping a keen eye on in the healthcare sector.
The information in this article should not be taken as advice. Readers should conduct their own due diligence and seek independent financial advice before making any investment decisions.
